DR info

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

18F-AV-1451
   Skåne University Hospital, Region Skåne
      2014   -   EUCTR2014-000422-38-SE   Sweden;
18F-FDG
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan;
18F-RO6958948
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom;
9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia;
AB1010
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain;
ABBV-8E12
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2018   Phase 2   EUCTR2017-001590-16-IT   Australia;Canada;Germany;Italy;United States;
      2017   Phase 2   EUCTR2016-001635-12-IT   Australia;Canada;Italy;United States;
   AbbVie
      2018   Phase 2   NCT03391765   Australia;Canada;France;Italy;Japan;United States;
      2018   Phase 1   NCT03413319   United States;
      2016   Phase 2   NCT02985879   Australia;Canada;France;Germany;Italy;Japan;Spain;United States;
   AbbVie Deutschland
      2019   Phase 2   EUCTR2017-001590-16-DE   Australia;Canada;Germany;United States;
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 2   EUCTR2016-001635-12-ES   Australia;Canada;Germany;Italy;Spain;United States;
      2017   Phase 2   EUCTR2016-001635-12-FR   Australia;Canada;France;Germany;Italy;Spain;United States;
      2017   Phase 2   EUCTR2016-001635-12-DE   Australia;Canada;Germany;Italy;Spain;United States;
AL-108
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States;
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States;
ASK Nr. 21972
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
AZP2006 oral solution
   AlzProtect SAS
      2020   Phase 2   NCT04008355   France;
Alpha-lipoic acid and L-acetyl carnitine
   Weill Medical College of Cornell University
      2010   Phase 1/Phase 2   NCT01537549   United States;
Anti-Parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Antisense oligonucleotide
   Novartis Pharmaceuticals
      2021   Phase 1   NCT04539041   Canada;Germany;United Kingdom;United States;
Apomorphine
   Fondation Ophtalmologique Adolphe de Rothschild
      2018   -   NCT04786158   France;
Azilect
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
BIIB092
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-002554-21-IT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   Biogen
      2017   Phase 2   NCT03068468   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 1   NCT02658916   United States;
      2015   Phase 1   NCT02460094   United States;
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-002554-21-GR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-GB   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-DE   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-AT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
BMS-986168
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   Bristol-Myers Squibb K.K.
      2017   Phase 2   JPRN-JapicCTI-173627   -
BMS986168
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Bepranemab
   UCB Biopharma SRL
      2019   Phase 1   NCT04185415   Belgium;Germany;Spain;United Kingdom;
Brain PET scan
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
CoQ10
   Lahey Clinic
      2004   Phase 2/Phase 3   NCT00532571   United States;
Coenzym Q10 Nanodispersion
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Coenzym Q10, Ubiquinon, Ubichinon
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Coenzyme Q10
   German Parkinson Study Group (GPS)
      2006   Phase 2   NCT00328874   Germany;
   Lahey Clinic
      2006   -   NCT00382824   United States;
DaTSCAN™ Ioflupane (123I) Injection
   GE Healthcare
      2020   Phase 3   NCT04193527   China;
Davunetide
   Allon Therapeutics
      2010   Phase 2/Phase 3   NCT01110720   Australia;Canada;France;Germany;United Kingdom;United States;
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States;
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States;
Davunetide (AL-108, NAP)
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States;
Deep Brain Stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Donepezil
   Groupe Hospitalier Pitie-Salpetriere
      2005   Phase 2   NCT00139373   France;
Droxidopa
   Loma Linda University
      2021   Phase 2   NCT03446807   United States;
Emeramide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
Example
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2000041207   China;
Exelon 1,5 mg Hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
Exelon 3,0 mg Hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
Exelon 6,0 mg Hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
F-18
   Chang Gung Memorial Hospital
      2018   Early Phase 1   NCT03625128   Taiwan;
F-18 AV 1451
   Mayo Clinic
      2015   -   NCT02605785   United States;
Fasudil
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT04734379   United States;
Flortaucipir F18
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
Flutemetamol
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   Japan;
Flutemetamol F18
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Fresh Frozen Plasma
   University of California, San Francisco
      2015   Phase 1   NCT02460731   United States;
GDNF & Synchro Med Infusion System
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00005903   United States;
Gold
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2000041207   China;
      2019   Phase 0   ChiCTR2000030512   China;
Hydrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Leucine
   Washington University School of Medicine
      2017   -   NCT03545126   United States;
Lithium
   Westat
      2008   Phase 1/Phase 2   NCT00703677   United Kingdom;United States;
N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NBMI
   EmeraMed
      2019   Phase 2   NCT04184063   Slovenia;
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NP031112
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom;
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Nitrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Placebo
   Bristol-Myers Squibb K.K.
      2017   Phase 2   JPRN-JapicCTI-173627   -
Pyruvate, creatine, niacinamide
   University of Louisville
      2004   -   NCT00605930   United States;
RASAGILINE MESILATE
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
RT001
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia;
   Retrotope, Inc.
      2021   Phase 2   NCT04937530   Germany;
Raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan;
Radiopharmaceuticals
   University of California, Berkeley
      2019   Early Phase 1   NCT03926702   United States;
Rasagilin
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
Rasagiline
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany;
Riluzole
   King's College London
      2000   Phase 3   NCT00211224   United Kingdom;
Rivastigmine
   Assistance Publique Hopitaux De Marseille
      2016   Phase 3   NCT02839642   France;
   University Hospital Tuebingen
      2008   Phase 2   NCT00522015   Germany;
Salsalate
   Adam Boxer
      2015   Phase 1   NCT02422485   United States;
Single dose C2N-8E12
   C2N Diagnostics
      2015   Phase 1   NCT02494024   United States;
Stem cell therapy
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2012   Phase 1/Phase 2   NCT01824121   Italy;
Sugar pill
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany;
Suvorexant
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States;
TPI 287 2 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 20 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 6.3 mg/m2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPN-101, 100 mg/day
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
TPN-101, 200 mg/day
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
TPN-101, 400 mg/day
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
Tideglusib
   Noscira SA
      2009   -   NCT01049399   Germany;Spain;United Kingdom;United States;
Trihexyphenidyl
   1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital
      2019   -   JPRN-UMIN000036522   Japan;
UCB0107 (bepranemab)
   UCB Biopharma SRL
      2020   Phase 1   NCT04658199   Belgium;Germany;Spain;United Kingdom;
Ubidecarenon
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Valproic acid
   Nantes University Hospital
      2006   Phase 2   NCT00385710   France;
Vizamyl (flutemetamol(F-18))
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
Water
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Zoledronic Acid 5Mg/Bag 100Ml Inj
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States;
Zolpidem
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States;
[18F] APN-1607
   Invicro
      2021   Phase 1   NCT05005819   United States;
[18F]-PI2620
   Life Molecular Imaging GmbH
      2022   Phase 1   NCT05187546   Germany;
      2020   Phase 1   NCT04715750   Germany;
[18F]Florbetapir
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03080051   United States;
      2016   Early Phase 1   NCT03058965   United States;
[18F]MNI-815 (MNI-815)
   Molecular NeuroImaging
      2015   Phase 0   NCT02531360   United States;
[18F]MNI-952
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03080051   United States;
[18F]MNI-958
   Invicro
      2018   Phase 1   NCT03545789   United States;
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03058965   United States;
[18F]T807 ([18F]MNI-777)
   Molecular NeuroImaging
      2014   Phase 1   NCT02103894   United States;
[F18]-FDDNP
   Fundacion Clinic per a la Recerca Biomédica
      2013   Phase 0   NCT02214862   Spain;